$SBBP News

Last published 4mo ago

4mo agoPVLA SVRA SLNO SBBP+2Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of DirectorsGlobeNewswireBrings more than 25 years of experience advancing and commercializing high-impact therapies for serious diseases, including those with limited or no approved treatment options Extensive public company and rare disease
3y agoSBBPApproval of Recorlev, Nda #214133 (Labeling)FDA Approved DrugsApproval Date: 08/16/2023; Drug Name: Recorlev, Nda #214133; Active Ingredients: LEVOKETOCONAZOLE; Company: Strongbridge; Submission Status: Approval; Submission Classification: Labeling; Application Number: 214133
5y agoSBBP XERSXeris Pharmaceuticals Completes Acquisition of Strongbridge BiopharmaBusiness WireXeris Pharmaceuticals, Inc. and Strongbridge Biopharma plc are now subsidiaries of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Xeris Pharmaceuticals, Inc. ("Xeris"), a pharmaceutical company leveraging its novel formulation technology platforms to d
5y agoSBBP XERSStrongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc.GlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the "Company" or "Strongbridge") today announced that the High Court of Ireland (the "Court") has approved the previously announced proposed
5y agoSBBPStrongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.GlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the "Company" or "Strongbridge") today announced that the High Court of Ireland (the "Court") has set the date of the final court hearing t
5y agoSBBP XERSXeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge BiopharmaBusiness WireXeris Pharmaceuticals, Inc. (NASDAQ:XERS) ("Xeris") today announced that its stockholders have voted to approve the previously announced proposed acquisition of Strongbridge Biopharma plc (NASDAQ:SBBP) ("Strongbridge") by Xeris. At the special meetin
5y agoSBBP XERSStrongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc.GlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the "Company" or "Strongbridge") today announced that its shareholders have voted to approve the previously announced proposed acquisition
5y agoSBBP XERSSecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote "FOR" the Transaction With XerisGlobeNewswireGlass Lewis Joins ISS in Recommending Strongbridge Shareholders Vote "FOR" Transaction with Xeris Strongbridge Urges Shareholders to Vote "FOR" All Transaction-Related Proposals DUBLIN, Ireland and TREVOSE, Pa., Aug. 31, 2021 (GLOBE NEWSWIRE) --
5y agoSBBP XERSLeading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders Vote "FOR" the Transaction With XerisGlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) ("Strongbridge") today announced that the leading independent proxy advisory firm Institutional Shareholder Services ("ISS") has recommended
5y agoSBBP XERSXeris Pharmaceuticals Announces Leading Independent Proxy Advisory Firm, ISS, Recommends Xeris Stockholders Vote "FOR" the Transaction With Strongbridge BiopharmaBusiness WireUrges stockholders to vote "FOR" all transaction-related proposals at the Xeris special meeting to be held virtually on September 14, 2021 Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) today announced that a leading independent proxy advisory firm Insti
5y agoSBBPStrongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswire~ Reports KEVEYIS® (dichlorphenamide) Second Quarter 2021 Revenue of $10.0 Million, a 28 Percent Increase Compared to $7.8 Million of Revenue During Second Quarter of 2020 ~ ~ Strongbridge Remains On-Track to Meet, or Potentially Exceed, the Top
5y agoSBBPStrongbridge Biopharma plc Announces Commencement of Mailing of Proxy StatementGlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (NASDAQ:SBBP) ("Strongbridge"), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare d
5y agoSBBPStrongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in IssueGlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (NASDAQ:SBBP) ("Strongbridge"), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare d
5y agoSBBPStrongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021GlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with sign
5y agoSBBPStrongbridge Biopharma plc Announces Dates of Special Shareholder Meetings in Connection with the Proposed Acquisition by Xeris Pharmaceuticals, Inc.GlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., July 26, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with signi
5y agoAXGN SBBP VSTMAxogen, Inc. Appoints John H. Johnson to Board of DirectorsGlobeNewswireALACHUA, Fla. and TAMPA, Fla., July 19, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that John H. Johnso
5y agoSBBPStrongbridge Biopharma plc Announces Publication of Long-term Efficacy and Safety Results for KEVEYIS® (dichlorphenamide) for the Treatment of Primary Periodic Paralysis in Muscle & NerveGlobeNewswire~ Study Confirms Long-Term Treatment with KEVEYIS is Safe and Effective for Chronic Use ~ ~ Analyses Provide Potentially Useful Information to Help Guide Clinician Patient Counseling & Management When Starting Treatment with KEVEYIS ~ DUBLIN, Irela
5y agoSBBPStrongbridge Biopharma plc Announces Issuance of Patent for RECORLEV® (levoketoconazole) for the Treatment of Cushing's SyndromeGlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., June 03, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with sign
5y agoSBBP XERSRule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare DiseasesPR NewswireCHICAGO and DUBLIN and TREVOSE, Pa., May 24, 2021 /PRNewswire/ -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formul
5y agoAMC FSKR METX NGM+1Thinking about buying stock in Meten Edtechx Education, AMC Entertainment, NGM Biopharmaceuticals, FS KKR Capital, or Strongbridge Biopharma?PR NewswireNEW YORK, May 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for METX, AMC, NGM, FSKR, and SBBP. To
5y agoSBBP XERSXeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare DiseasesBusiness WireTransaction Creates Fast-Growing Biopharmaceutical Company with Two Commercial Assets and Robust Clinical Pipeline with Multiple Near-term Inflection Points Diversifies Revenue Base with Two Rapidly Growing Brands in Xeris' Gvoke® and Strongbridge'
5y agoSBBP XERSRule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma Plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare DiseasesBusiness WireNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION THIS ANNOUNCEMENT IS BEING MADE PURSUANT TO RULE
5y agoSBBPStrongbridge Biopharma plc Announces U.S. Food & Drug Administration (FDA) Filing Acceptance of New Drug Application (NDA) for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing's SyndromeGlobeNewswire~ FDA Sets Prescription Drug User Fee Act (PDUFA) Target Action Date of January 1, 2022 ~ ~ If Approved, RECORLEV® (levoketoconazole) Launch Planned for First Quarter of 2022 ~ DUBLIN, Ireland and TREVOSE, Pa., May 13, 2021 (GLOBE NEWSWIRE)
5y agoSBBPStrongbridge Biopharma plc Reports First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswire~ Reports KEVEYIS® (dichlorphenamide) First Quarter 2021 Revenue of $8.4 Million, a 25 Percent Increase Compared to $6.7 Million of Revenue During First Quarter of 2020 ~ ~ Reiterates Full-Year 2021 KEVEYIS® (dichlorphenamide) Revenue Guidance
5y agoSBBPStrongbridge Biopharma Plc to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 12, 2021 / Strongbridge Biopharma Plc (NASDAQ:SBBP) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 12, 2021 at 8:30 AM Eastern Time. To listen to the event live or ac
5y agoSBBPStrongbridge Biopharma plc to Host First Quarter 2021 Financial Results Conference Call on May 12, 2021GlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., May 06, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with signi
5y agoSBBPStrongbridge Biopharma plc Announces Publication of Diabetes Subgroup Analysis from Phase 3 SONICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome in Frontiers in EndocrinologyGlobeNewswireRECORLEV® (levoketoconazole) Treatment Demonstrates Clinically Meaningful Improvements in Cortisol Control and Clinical Benefit in Patients with Cushing’s Syndrome and Comorbid Diabetes Mellitus ...
5y agoSBBPStrongbridge Biopharma plc Presents Detailed Results from Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2021 Annual Meeting of the Endocrine Society (ENDO)GlobeNewswire~ As Previously Reported, LOGICS Met its Primary Endpoint with Statistical Significance ~ ~ Strongbridge Recently Submitted a New Drug Application (NDA) for RECORLEV® (levoketoconazole) to the U.S....
5y agoSBBPStrongbridge Biopharma plc to Present at Oppenheimer’s 31st Annual Healthcare ConferenceGlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., March 15, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
5y agoSBBPStrongbridge Biopharma plc Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate UpdateGlobeNewswire~ Submitted New Drug Application (NDA) for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome to U.S. Food & Drug Administration ~ ~ KEVEYIS® (dichlorphenamide)...
5y agoSBBPStrongbridge Biopharma plc Announces Submission of New Drug Application for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome to the U.S. Food & Drug AdministrationGlobeNewswire~ RECORLEV® (levoketoconazole) New Drug Application is Supported by Previously-Reported Positive and Statistically Significant Results from the Phase 3 SONICS and LOGICS Studies ~ ~ Nearly 40 Percent...
5y agoSBBPStrongbridge Biopharma plc to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call on March 3, 2021GlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
5y agoSBBPStrongbridge Biopharma plc Announces Promotion of Richard S. Kollender to President and Chief Financial OfficerGlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
5y agoSBBPStrongbridge Biopharma plc Announces New Employment Inducement AwardsGlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
5y agoSBBPStrongbridge Biopharma plc Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate UpdateGlobeNewswire~ Expects to Report KEVEYIS® (dichlorphenamide) Fourth Quarter 2020 Revenue of Approximately $8.2 Million and Full-Year 2020 Revenue of Approximately $30.7 Million, a 41.5 Percent Increase over 2019...
5y agoSBBPStrongbridge Biopharma plc Announces Publication of Secondary Endpoints Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome in the Journal, PituitaryGlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
6y agoSBBPStrongbridge Biopharma plc Announces Participation in Two Upcoming Investor ConferencesGlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the...
6y agoSBBPStrongbridge Biopharma plc (SBBP) CEO John Johnson on Q3 2020 Results - Earnings Call TranscriptEarnings Call Transcripts
6y agoSBBPStrongbridge Biopharma plc Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewswire~ Company on Track to Submit New Drug Application (NDA) for RECORLEV® (levoketoconazole) to the FDA in the First Quarter of 2021 Following the Reporting of Positive Top-line Data from the LOGICS Study...
6y agoSBBPStrongbridge Biopharma plc to Host Third Quarter 2020 Financial Results Conference Call on October 29, 2020GlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
6y agoSBBPStrongbridge Biopharma plc Announces Pricing of Public Offering of Ordinary SharesGlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
6y agoSBBPStrongbridge Biopharma plc Announces Proposed Public Offering of Ordinary SharesGlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
6y agoSBBPStrongbridge Biopharma plc Provides Corporate UpdateGlobeNewswire~ Company Reported Positive and Statistically Significant Top-Line Results from the Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome; To...
6y agoSBBPStrongbridge Biopharma plc Announces Positive and Statistically Significant Top-Line Results from the Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s SyndromeGlobeNewswire~ LOGICS Study Met Primary Endpoint with High Statistical Significance; Results at the End of the Randomized-Withdrawal Phase of the Study Demonstrated that Withdrawing Patients to Placebo...
6y agoSBBPStrongbridge Biopharma plc's (SBBP) CEO John Johnson on Q2 2020 Results - Earnings Call TranscriptEarnings Call Transcripts
6y agoSBBPStrongbridge Biopharma plc Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewswire~ Reports KEVEYIS® (dichlorphenamide) Second Quarter 2020 Revenue of $7.8 Million, a 28 Percent Increase Compared to $6.1 Million During Second Quarter of 2019 ~ ~ Company Expects to Report Top-Line...
6y agoSBBPStrongbridge Biopharma plc to Host Second Quarter 2020 Financial Results Conference Call on August 4, 2020GlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., July 28, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
6y agoSBBPStrongbridge Biopharma plc Announces Appointment of John H. Johnson to Chief Executive OfficerGlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
6y agoSBBPStrongbridge Biopharma plc Announces Last Patient Completes Last Study Visit in the Randomized Withdrawal Phase of the LOGICS Trial Evaluating RECORLEV® (levoketoconazole) for Endogenous Cushing’s SyndromeGlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., July 01, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...
6y agoSBBPStrongbridge Biopharma plc to Present at the Jefferies Virtual Healthcare ConferenceGlobeNewswireDUBLIN, Ireland and TREVOSE, Pa., June 01, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...